Oxford VR, a spinout from Oxford University's Department of Psychiatry that wants to use VR simulations to treat mental health problems, raises £10M Series A
Annie Musgrove / Tech.eu : Tweets: @yoda Tweets: Drew Olanoff / @yoda : What company is going to solve the mental problems they cause https://twitter.com/...
Context & Ripple Effects
Oxford VR is an academic spinout — built out of Oxford University's Department of Psychiatry rather than a consumer lab — and its £10M Series A funds the push from clinical research into productized VR therapy for mental health problems.
The raise sits inside a broader wave of venture money for clinical VR: Osso VR scaled from a $14M Series A to a $66M Series C for surgical training over the same period, and within eighteen months of this round Rey launched and raised a $26M Series A delivering on-demand mental health care powered by OxfordVR's own tools.
First-order effects
- The £10M gives Oxford VR the runway to turn its psychiatry-department treatment protocols into deployable VR therapy programs, moving them beyond the university lab toward patients and health systems.
Second-order effects
- The technology becomes supply for other startups: Rey's on-demand mental health service is built directly on OxfordVR-powered tools, meaning Oxford VR's Series A effectively seeds a downstream care-delivery company rather than only its own end-user product.
- Osso VR's escalating rounds show investors treating VR-based clinical software as a repeatable category, pulling more capital toward adjacent verticals like surgical training alongside mental health treatment.
Third-order effects
- If the pattern holds, academic psychiatry research increasingly reaches patients through venture-backed intermediaries — universities supplying the clinical evidence while spinouts and their licensees own the delivery channel — shifting mental health care from clinician-led sessions toward on-demand, headset-based programs.
The trend: Clinical VR is moving from university research labs to venture-backed platforms, with spinout IP like OxfordVR's powering downstream care-delivery companies.